ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VAL Valirx Plc

3.45
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.45 3.40 3.50 3.45 3.45 3.45 1,543,287 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.32 3.11M
Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 3.45p. Over the last year, Valirx shares have traded in a share price range of 3.45p to 14.75p.

Valirx currently has 90,174,156 shares in issue. The market capitalisation of Valirx is £3.11 million. Valirx has a price to earnings ratio (PE ratio) of -1.32.

Valirx Share Discussion Threads

Showing 24876 to 24897 of 29350 messages
Chat Pages: Latest  1006  1005  1004  1003  1002  1001  1000  999  998  997  996  995  Older
DateSubjectAuthorDiscuss
28/7/2022
07:23
Plenty holdings the baby here ....
amaretto1
28/7/2022
07:22
I'd say 5 pence max ....
amaretto1
27/7/2022
16:39
Looks closer to getting into single figures than the teens to be honest
tburns
27/7/2022
16:27
ah there is the big sell had to be, hopefully the last of the placing shares
ianjan
27/7/2022
16:12
The market is always on the ball and can see this shambles from what it is that is why we are heading back into the teens!!
pinkpudycat
27/7/2022
15:57
whats with the trades today over 350k more buys than sells yet we are down must be a large sell after hours, hopefully to clear whoever is still selling down here
ianjan
27/7/2022
15:53
Added a little today . An easy bagger from here in the near term .
jungmana
27/7/2022
14:14
Exactly mate
ben gibbons
27/7/2022
07:19
PM2022 on the last twitter rampathon 60/40 split in favour of it being true I remember you stating.Hope you never play Russian roulette because I don't favour your odds of winning bro ;-)
ben gibbons
27/7/2022
07:12
What a massive surprise - not.No RNS this morning announcing a massive deal.Lol.
ben gibbons
27/7/2022
06:48
PM2022 over on LSEStock house tweet has been liked and retweeted and not refuted by Suzy therefore must be genuine.Lol what a muppet.Fact - it would have been rns'd because it's price sensitive.Fact - it has glaringly obvious grammar and spelling mistakes.Fact - PM2022 is an idiot who also thinks southerninvestor is porky on a second account when anyone who compares their conversational manner can see they are not the same person.
ben gibbons
26/7/2022
16:56
Probably a fake ramp. There are some spelling mistakes as well so I think it's fake.
ben gibbons
26/7/2022
16:56
That article was written at 10:31am uk time so sure it would have been rns'd if it was accurate.
ben gibbons
26/7/2022
16:48
No worries link already here.
ben gibbons
26/7/2022
16:47
Where did you get that from. Link please?
ben gibbons
26/7/2022
16:29
Huge news if article is correct.ValiRx and TheoremRx - VAL201 - US$61M plus royaltiesDr Ken Sorensen, Chairman of TheoremRx We are delighted out latest fundraising od $250m has brought in multiple financial institutions as we now move forward with our strategic plans.Dr Ken Sorensen, Chairman of TheoremRx stated: "We have appreciated the work carried out so far, and we will now move forward with VAL201 as it is an important part of our pipeline of new projects."First payments to ValiRx are expected on or before the end of July.The proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer. The potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx. The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of July 2022.
aimtrader2
26/7/2022
11:01
Also a saleable product Not a life style company Roll on the next 15 year's VAL .... equals Top Gun 8 release ! Lol
amaretto1
26/7/2022
10:23
Get the placing churn done and should see 20p in quick time.Went up over 500% in a few weeks after the last placing .
jungmana
26/7/2022
10:13
Same old story with valirx then, not going anywhere from what I can see... Only time will tell...
tonythemanwithnoname
26/7/2022
09:30
Agreed Amaretto prefers cos with huge debt and huge cash burn ..this isn't for him.
nico115
26/7/2022
08:38
GBP 10m market cap right now with cash of GBP 2.5m .Too cheap for val imo.
jungmana
25/7/2022
22:35
Monkey boy the Guru on VAL ..He's been on Advfn since April 22 ...
amaretto1
Chat Pages: Latest  1006  1005  1004  1003  1002  1001  1000  999  998  997  996  995  Older

Your Recent History

Delayed Upgrade Clock